A Phase II study of 5-fluorouracil, bevacizumab, and radiation followed by modified FOLFOX6 [oxaliplatin, fluorouracil, folinic acid] and bevacizumab in the adjuvant treatment of patients with stage I/II rectal cancer

Trial Profile

A Phase II study of 5-fluorouracil, bevacizumab, and radiation followed by modified FOLFOX6 [oxaliplatin, fluorouracil, folinic acid] and bevacizumab in the adjuvant treatment of patients with stage I/II rectal cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 May 2011 Planned End Date changed from 1 Jun 2010 to 1 Aug 2011 as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 20 Jan 2009 Planned end date changed from 1 Mar 2009 to 1 Jun 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top